Proteasome 20S subunit beta (PSMB) (PSMB)

The proteasome catalytic subunits are the enzymatic components of the 20S core particle within the 26S proteasome complex, which is responsible for the ATP-dependent degradation of polyubiquitinated proteins (UniProt: P28074). The catalytic activity resides in the beta subunits—specifically PSMB5 (beta-5), PSMB2 (beta-2), and PSMB1 (beta-1)—which possess chymotrypsin-like, trypsin-like, and caspase-like proteolytic activities, respectively (PubMed: 15546999). These subunits are essential for maintaining cellular proteostasis, regulating the cell cycle, and modulating signal transduction pathways like NF-kappaB (StatPearls: NBK542311). In malignant cells, particularly plasma cells in multiple myeloma, there is a high dependency on proteasome activity to manage the stress of excessive protein production (PubMed: 28103133). Therapeutic inhibition of these subunits leads to the accumulation of misfolded proteins and pro-apoptotic factors, triggering programmed cell death. Proteasome inhibitors such as bortezomib and carfilzomib have become standard-of-care treatments for hematologic malignancies (NIH: National Cancer Institute). Beyond cancer, these subunits are also being investigated as targets for inflammatory and autoimmune conditions due to their role in antigen processing and cytokine signaling. The development of second-generation inhibitors aims to improve subunit specificity and reduce off-target toxicities like peripheral neuropathy.

Other names

Proteasome catalytic subunits20S proteasomeMulticatalytic endopeptidase complexBeta subunitsPSMB5PSMB1PSMB2Immunoproteasome subunits

Inhibition of the N-terminal threonine residue of the beta subunits, primarily the chymotrypsin-like activity of PSMB5, leading to the accumulation of ubiquitinated proteins and induction of apoptosis (PubMed: 15546999).